Browse the corpus

REFERENCES Aivado M, Schulte K, Henze L, et al, “Bendamustine in the Treatment of Chronic Lymphocytic Leukemia: Results and Future Perspectives,” Semin Oncol , 2002, 29(4 Suppl 13):19-22. [PubMed 12170428 ] Cheson BD, Wendtner CM, Pieper A, et al, “Optimal Use of Bendamustine in Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphomas, and Multiple Myeloma: Treatment Recommendations From an International Consensus Panel,” Clin Lymphoma Myeloma Leuk , 2010, 10(1):21-7. [PubMed 20223726 ] Dubbelman AC, Rosing H, Darwish M, et al, “An Open-Label Phase I Pharmacokinetic Study of [ 14 c] Bendamustine in Patients with Relapsed or Refractory Malignancy,” Blood , 2011, 118(21):2746 [abstract 2746 from 2011 ASH Annual Meeting] Fischer K, Cramer P, Busch R, et al, “Bendamustine Combined With Rituximab in Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia: A Multicenter Phase II Trial of the German Chronic Lymphocytic Leukemia Study Group,” J Clin Oncol , 2011, 29(26):3559-66. [PubMed 21844497 ] Fischer K, Cramer P, Busch R, et al, “Bendamustine in Combination With Rituximab for Previously Untreated Patients With Chronic Lymphocytic Leukemia: A Multicenter Phase II Trial of the German Chronic Lymphocytic Leukemia Study Group,” J Clin Oncol , 2012, 30(26):3209-16. [PubMed 22869884 ] Fowler N, Kahl BS, Lee P, et al, “Bortezomib, Bendamustine, and Rituximab in Patients With Relapsed or Refractory Follicular Lymphoma: The Phase II VERTICAL Study,” J Clin Oncol , 2011, 29(25):3389-95. [PubMed 21810687 ] Friedberg JW, Cohen P, Chen L, et al, “Bendamustine in Patients With Rituximab-Refractory Indolent and Transformed Non-Hodgkin's Lymphoma: Results From a Phase II Multicenter, Single-Agent Study,” J Clin Oncol , 2008, 26(2):204-10. [PubMed 18182663 ] Friedberg JW, Vose JM, Kelly JL, et al, “The Combination of Bendamustine, Bortezomib, and Rituximab for Patients With Relapsed/Refractory Indolent and Mantle Cell Non-Hodgkin Lymphoma,” Blood , 2011, 117(10):2807-12. [PubMed 21239695 ] Iannitto E, Morabito F, Mancuso S, et al, “Bendamustine With or Without Rituximab in the Treatment of Relapsed Chronic Lymphocytic Leukaemia: An Italian Retrospective Study,” Br J Haematol , 2011, 153(3):351-7. [PubMed 21371003 ]

Friedberg JW, Vose JM, Kelly JL, et al, “The Combination of Bendamustine, Bortezomib, and Rituximab for Patients With Relapsed/Refractory Indolent and Mantle Cell Non-Hodgkin Lymphoma,” Blood , 2011, 117(10):2807-12. [PubMed 21239695 ] Iannitto E, Morabito F, Mancuso S, et al, “Bendamustine With or Without Rituximab in the Treatment of Relapsed Chronic Lymphocytic Leukaemia: An Italian Retrospective Study,” Br J Haematol , 2011, 153(3):351-7. [PubMed 21371003 ] Kahl BS, Bartlett NL, Leonard JP, et al, “Bendamustine Is Effective Therapy in Patients With Rituximab-Refractory, Indolent B-Cell Non-Hodgkin Lymphoma: Results From a Multicenter Study,” Cancer , 2010, 116(1):106-14. [PubMed 19890959 ] Knauf WU, Lissitchkov T, Aldaoud A, et al, “Bendamustine Compared With Chlorambucil In Previously Untreated Patients With Chronic Lymphocytic Leukaemia: Updated Results of a Randomized Phase III Trial,” Br J Haematol , 2012, 159(1):67-77. [PubMed 22861163 ] Knauf WU, Lissichkov T, Aldaoud A, et al, “Phase III Randomized Study of Bendamustine Compared With Chlorambucil in Previously Untreated Patients With Chronic Lymphocytic Leukemia (B-CLL),” J Clin Oncol , 2009, 27(26):4378-84. [PubMed 19652068 ] Knop S, Straka C, Haen M, et al, “The Efficacy and Toxicity of Bendamustine in Recurrent Multiple Myeloma After High-Dose Chemotherapy,” Haematologica , 2005, 90(9):1287-8. [PubMed 16154860 ] Michael M, Bruns I, Bölke E, et al, “Bendamustine in Patients With Relapsed or Refractory Multiple Myeloma,” Eur J Med Res , 2010, 15(1):13-9. [PubMed 20159666 ] Moskowitz, AJ, Hamlin PA, Gerecitano J, et al, “Bendamustine is Highly Active in Heavily Pre-Treated Relapsed and Refractory Hodgkin Lymphoma and Serves as a Bridge to Allogeneic Stem Cell Transplant,” Blood , 2009, 114(22):720 [abstract 720 from 2009 ASH Annual Meeting]. National Institute for Occupational Safety and Health (NIOSH), "NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012." Available at file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf . Accessed January 21, 2013. Nordstrom BL, Knopf KB, Teltsch D, et al, “Retrospective safety assessment of bendamustine in patients with renal impairment,” J Clin Oncol , 2012, 30(15s):e13018 [abstract e13018 from 2012 ASCO Annual Meeting].

National Institute for Occupational Safety and Health (NIOSH), "NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012." Available at file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf . Accessed January 21, 2013. Nordstrom BL, Knopf KB, Teltsch D, et al, “Retrospective safety assessment of bendamustine in patients with renal impairment,” J Clin Oncol , 2012, 30(15s):e13018 [abstract e13018 from 2012 ASCO Annual Meeting]. Owen JS, Melhem M, Passarell JA, et al, “Bendamustine Pharmacokinetic Profile and Exposure-Response Relationships in Patients With Indolent Non-Hodgkin's Lymphoma,” Cancer Chemother Pharmacol , 2010, 66(6):1039-49. [PubMed 20140617 ] Pérez Fidalgo JA, García Fabregat L, Cervantes A, et al, “Management of Chemotherapy Extravasation: ESMO-EONS Clinical Practice Guidelines,” Ann Oncol , 2012, 23(Suppl 7):167-73. [PubMed 22997449 ] Ponisch W and Niederwieser D, “Bendamustine in the Treatment of Multiple Myeloma: Results and Future Perspectives,” Semin Oncol , 2002, 29(4 Suppl 13):23-6. [PubMed 12170429 ] Robinson KS, Williams ME, van der Jagt RH, et al, “Phase II Multicenter Study of Bendamustine Plus Rituximab in Patients With Relapsed Indolent B-Cell and Mantle Cell Non-Hodgkin's Lymphoma,” J Clin Oncol , 2008, 26(27):4473-9. [PubMed 18626004 ] Rummel MJ, Al-Batran SE, Kim SZ, et al, “Bendamustine Plus Rituximab is Effective and has a Favorable Toxicity Profile in the Treatment of Mantle Cell and Low-Grade Non-Hodgkin's Lymphoma,” J Clin Oncol , 2005, 23(15):3383-9. [PubMed 15908650 ] Rummel MJ, Niederle N, Maschmeyer G, et al, “Bendamustine Plus Rituximab (B-R) versus CHOP Plus Rituximab (CHOP-R) as First-Line Treatment in Patients With Indolent and Mantle Cell Lymphomas (MCL): Updated Results From the StiL NHL1 Study,” J Clin Oncol , 2012, 30(15s):3 [abstract 3 from 2012 ASCO Annual Meeting]. Rummel MJ, Niederle N, Maschmeyer G, et al, “Bendamustine Plus Rituximab is Superior in Respect of Progression Free Survival and CR Rate When Compared to CHOP Plus Rituximab as First-Line Treatment of Patients With Advanced Follicular, Indolent, and Mantle Cell Lymphomas: Final Results of a Randomized Phase III Study of the StiL (Study Group Indolent Lymphomas, Germany),” Blood , 2009, 114(22):405 [abstract 405 from 2009 ASH Annual Meeting]

Rummel MJ, Niederle N, Maschmeyer G, et al, “Bendamustine Plus Rituximab is Superior in Respect of Progression Free Survival and CR Rate When Compared to CHOP Plus Rituximab as First-Line Treatment of Patients With Advanced Follicular, Indolent, and Mantle Cell Lymphomas: Final Results of a Randomized Phase III Study of the StiL (Study Group Indolent Lymphomas, Germany),” Blood , 2009, 114(22):405 [abstract 405 from 2009 ASH Annual Meeting] Tapan U, May SK, Fiore J, et al, “Reactivation of Hepatitis B Virus Following Bendamustine-Containing Chemotherapy in a Patient With Multiple Myeloma,” Leuk Lymphoma , 2011, 52(5):916-8. [PubMed 21306291 ] Teichert J, Baumann F, Chao Q, et al, “Characterization of Two Phase I Metabolites of Bendamustine in Human Liver Microsomes and in Cancer Patients Treated With Bendamustine Hydrochloride,” Cancer Chemother Pharmacol , 2007, 59(6):759-70. [PubMed 16957931 ] Teichert J, Sohr R, Baumann F, et al, “Synthesis and Characterization of Some New Phase II Metabolites of the Alkylator Bendamustine and Their Identification in Human Bile, Urine, and Plasma From Patients With Cholangiocarcinoma,” Drug Metab Dispos , 2005, 33(7):984-92. [PubMed 15845750 ] Treon SP, Hanzis C, Tripsas C, et al, “Bendamustine Therapy in Patients With Relapsed or Refractory Waldenström's Macroglobulinemia,” Clin Lymphoma Myeloma Leuk , 2011, 11(1):133-5. [PubMed 21454214 ] Topic 9323 Version 40.0 © 2013 UpToDate, Inc. All rights reserved. | Subscription and License Agreement | Release: 21.6- C21.56 Licensed to: AsanBook Dig. Med. Lib. | Support Tag: [1104-202.43.93.2-481E12C6DB-S244013.14]